Allogeneic hematopoietic SCT (HSCT) appears to be an efficient tool to cure high-risk AML in first CR but the choice between BUbased or TBI-based conditioning regimens still remains controversial. In order to analyze the impact of conditioning regimen on long-term survival, we conducted a retrospective analysis from French registry data including all consecutive patients under 18 years old (n ¼ 226) from 1980 to 2004 transplanted for AML in CR1 from sibling (n ¼ 142) or matched unrelated donors and given either TBI-1200 cGy and CY 120 mg/kg (TBI-Cy, n ¼ 84) or BU 16 mg/kg and CY 200 mg/kg (BuCy200, n ¼ 142). Patient subgroups were comparable for all criteria except for median age at diagnosis and HSCT and for donor type. Both 5-year OS and disease-free survival (DFS) were significantly better in BuCy200 group (P ¼ 0.02 and 0.005, respectively). In multivariate analysis, both HLA matching and BuCy200 appeared as good prognostic factors for treatment-related mortality and DFS. Grade 2-4 acute GvHD and chronic GvHD rates were statistically higher in TBI-Cy group than in Bu-Cy200 one with a RR at 2 (P ¼ 0.002). In total, Bu-Cy200 conditioning regimen gives better outcome compared with TBI-Cy irrespective of the stem cell source and the donor type.
INTRODUCTION
In addition to conventional intensive therapy based on cytarabine and anthracycline association, allogeneic hematopoietic SCT (HSCT) appears to be an efficient tool to cure AML in first CR (CR1) in patients o18 years of age. [1] [2] [3] Even though AML prognostic or risk classification is worldwide based on karyotype and molecular markers, the indication of HSCT in CR1 differs from one cooperative group to the other. 4 Until recently, we-the French group-indicated allogeneic HSCT for all patients-except those with t(15;17) or t(8;21)-in CR1 and having a sibling donor. 2, 5 In the same period, indications of HSCT were extended to patients without a sibling donor and presenting with poor prognosis AML, that is, mixed lineage leukemia rearrangement (or 11q23 mutation), monosomy 7, t(6;9), FLT3-TID. [6] [7] [8] [9] [10] [11] Whatever the considered group of patients with HSCT indication in CR1, conditioning regimen modalities still have to be discussed since, so far, no pediatric consensus exists. To date, if a wide majority of pediatric transplant groups agree for using the myeloablative conditioning regimen, the choice between BU-based or TBI-based conditioning regimen still remains controversial in some parts of the world, except COG North America, Australia and New Zealand, where TBI was totally abandoned. However, including those in North America, some groups still continue using TBI-based conditioning regimen. 12, 13 Then, we conducted a retrospective study to analyze the impact of conditioning regimen on the longterm OS of children who underwent HSCT for AML in CR1. We report the results regarding patients o18 years who received allogeneic HSCT from either sibling or alternative donor in France from 1980 to 2004 after myeloablative TBI-based conditioning regimen or Bu-based conditioning regimen for AML in CR1. This study received the agreement of both the scientific committee and institutional review board of SFGM-TC.
PATIENTS AND METHODS

This analysis was based on data reported to the SFGM-TC (Socié té
We analyzed all consecutive patients who underwent allogeneic HSCT after two different myeloablative conditioning regimens, either 1200 cGy TBI-CY 120 mg/kg total dose association (TBI-Cy) or BU-CY 200 mg/kg total dose association (Bu-Cy200). Both HSCT indication and choice between these two different conditioning regimens were at the discretion of each physician. Then, some patients with good-risk karyotype (see below for definition) underwent HSCT and were included in this study. We excluded patients over 18 years of age, patients with AML M3, patients who received another conditioning regimen and patients who received two or more HSCT.
The initial diagnosis of AML was made at the referring institution. Primary treatment for leukemia varied according to practice at the referring institution, that is, LAME protocols or CLG-EORTC AML protocols. Remission was defined as a complete response to chemotherapy in the BM, that is, o5% blasts associated with normal marrow cellularity. Data included characteristics of both patient and donor age, gender, dates of diagnosis and transplantation, initial cytogenetic or molecular risk, initial leukocyte count, time from diagnosis to graft, age at graft, donor and recipient CMV status, source of stem cell, HLA matching, sex mismatch defined by a gender difference between donor and recipient, GvHD prophylaxis and period of HSCT: before or after 2000.
Cytogenetic risk was defined as follows: good risk for patients with inv 16, t(8; 21) or t(9;11); poor risk for patients with À 7, À 5/5q À , 3q abnormality, mixed lineage leukemia rearrangement, t(6;9) or complex karyotype; intermediate risk for all other patients. 14, 15 Depending on the center and/or transplantation time, TBI was given as a single dose or fractionated doses. Differences between these two techniques appeared mainly in long-term side effects. 16 As we did not perform any analysis regarding specific long-term side effects (such as second tumors or cataracts), we have chosen to analyze all together patients who underwent allogeneic HSCT after either mono or multi-fractionated TBI. However, the wide majority of irradiated patients in this cohort received 1200 cGY delivered in six fractions on 3 consecutive days. The total dose of CY was 120 mg/kg of recipient body weight on 2 consecutive days for TBI-Cy. Total dose of BU was either 16 mg/kg for oral intake (before 2004) or adapted to recipient body weight for i.v. administration (after 2004), split four times a day for 4 consecutive days followed by CY 50 mg/kg/day for 4 additional days (that is, 200 mg/kg total dose) for Bu-Cy200. 17 Supportive care remained at the discretion of the local physician. Depending on the transplantation period, HLA typing was done either by serological or molecular method for HLA class I and by middle-or high-resolution molecular method for HLA class II (before and after 2000). Then, the oldest enrolled patients received a transplant from a 6/6 compatible donor whereas the more recent ones received a 10/10 compatible graft. Any other cases were considered as partially matched donor recipient pairs. GvHD prophylaxis varied from one transplantation center to another one and through the time acute and chronic GvHD were diagnosed and staged according to the standard criteria. Only patients who had evidence of engraftment at any time were considered for aGvHD incidence analysis. Patients who survived for at least 100 days with sustained engraftment were considered for cGvHD incidence analysis. Neutrophil engraftment was defined as the first day with a neutrophil count 40.5 Â 10 9 /L for 3 consecutive days. Platelet engraftment was defined as the first day with platelet count 450 Â 10 9 /L for 3 consecutive days without any platelet transfusion for 7 days. Relapse was defined by detection of any type of disease progression, that is, 45% of leukemic cells in marrow aspiration, detection on leukemic cells outside BM (skin, central nervous system and so on) or positive molecular disease-above significant level-on at least two consecutive molecular controls. The time of relapse was calculated from the date of transplantation. Disease-free survival (DFS) included patients who were alive without relapse at a given time. OS included all alive patients at a given time irrespective of their disease status. Transplant-related mortality included all dead patients of other cause than disease or relapse. Follow-up was calculated from the transplantation date to the date of last news (death or last medical contact). Duration of follow-up for the patient population was defined as elapsed time from transplantation to the last follow-up.
STATISTICAL ANALYSIS
Statistical analyses were performed according to the statistical guidelines for EBMT. 18 OS and DFS were analyzed by the Kaplan-Meier method and log-rank test. Relapse incidence, acute and chronic GvHD cumulative incidences were analyzed by the Gray Test and, for the multivariate analysis, by the application of the proportional hazard model for the sub-distribution of competing risks, by Fine and Gray method. For relapse incidence, the censored cases were patients alive without relapse at last contact and the competing event was death without evidence of relapse. For aGvHD incidence, the censored cases were those patients alive with no occurrence of aGvHD at 100 days and the competing event was death without aGvHD within 100 days. For cGvHD incidence, the censored cases were patients alive with no occurrence of cGvHD at last contact and the competing event was death without evidence of cGvHD after D100.
Multivariate analyses of OS, DFS and TRM were performed to adjust differences in event time distributions for the effect of several prognostic factors acting simultaneously, using the Cox regression model and Fine-Gray model for relapse incidence. Criteria for selection of covariates which were initially included in the model were parameter with P-value o0.2 on univariate analysis. Improvement of the model occurred by elimination of non-significant factors, using a stepwise 'backward process'. All analyses were performed by using SAS 9.0 (SAS Institute, Cary, NC, USA) and R statistical software (The R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patients characteristics
Two-hundred and twenty-six patients were registered in the SFGM-TC database for a first allogeneic HSCT after either TBIbased (n ¼ 84) or Bu-based (n ¼ 142) myeloablative conditioning regimen as treatment for AML between July 1980 and December 2004. TBI dose 1200 cGY was administered in 96.4% of patients. Indication and choice between the two different conditioning regimens were at the discretion of each physician. GvHD prophylaxis was mainly based on methotrexate-cyclosporine A association±ATG. Ninety-one patients (40%) underwent HSCT before 1 January 2000 of whom 38 (42%) received TBI-based conditioning regimen. One hundred and thirty-five patients (60%) underwent HSCT after 1 January 2000 of whom 46 (34%) received TBI-based conditioning regimen.
Median follow-up for all patients was 59 months (range: 0.2-264).
The main patient characteristics for these two groups are summarized in Table 1 . There was no statistically significant difference between the two groups for date of HSCT, gender, median initial leukocyte count, cytogenetic stratification group, donor-recipient sex-mismatch and donor-recipient CMV serological status, and for median time from diagnosis to HSCT.
The two compared populations differed significantly for donor type with more patients with a matched unrelated donor in the TBI-Cy group (P ¼ 0.0001).
Median age at diagnosis was 13.1 years (range 1.6-17.6 years) and 6.0 (0-17.7 years) for patients given TBI-Cy and Bu-Cy200, respectively (Po0.001). Median age at HSCT was 13.7 years (range: 2.6-17.9 years) vs 6.8 (range 0.5-17.9 years) for patients given TBI-Cy conditioning and Bu-Cy200, respectively (Po0.001). Median time from diagnosis to HSCT was 5.6 months (range 3.8-6.3) vs 4.5 months (range 3.6-7.3) for patients given TBI-Cy and Bu-Cy200, respectively (P ¼ 0.1). One hundred and ten patients (49%) were older than 10 years at transplantation. Among 209 (92% of patients) assessable patients for cytogenetics, 68% had intermediate-risk, 9% had good-risk despite the absence of formal indication and 23% had poor-risk cytogenetics. Despite the difference in median age in these two groups and the probability for having more poor-risk cytogenetics in older patients, there was no difference between the two groups of patients regarding cytogenetics. It could be assumed that older patients may present more frequently poor-risk cytogenetic abnormalities than younger. However, this hypothesis was indirectly eliminated as patient age appeared as not significant in univariate analysis and then has been suppressed for multivariate analysis (see below). Median time from initial diagnosis to transplantation was 4.7 months (2.2-7). According to their treatment protocol, patients received two or three standard chemotherapy courses before transplantation. Stem cell source was BM in 216 patients (95.6%), cord blood in 4 patients (1.8%) and peripheral blood in 6 patients (2.6%) with no significant difference between the two groups. One hundred and forty-two patients (63%) had a matched sibling donor, 69 (31%) had a full matched unrelated donor and 15 (6%) had a partial mismatched related or unrelated donor. Thirty-three male patients (15%) received grafts from female donors. Fifty patients (22%) with CMV sero-positive status received grafts from donors with sero-negative status CMV and then presented with poor-risk CMV serology disparity.
Engraftment
Median time engraftment did not differ between the two groups: 20 days in the Bu-Cy200 group and 21 in the TBI group (P ¼ 0.6) for neutrophils and 39 days in the Bu-Cy200 group and 27 in the TBI group (P ¼ 0.3) for platelets.
Overall survival At the end of the study, 135 patients were alive, 84 died and 7 were lost at follow-up. By Kaplan-Meier analysis, 5-and 10-year OS for the whole cohort was 62.5% and 61.8%, respectively. Five-and 10-year OS were better for patients given Bu-Cy200 conditioning regimen than for those who received TBI-Cy with 67.8% (95% CI 59.4-76.2%) and 52.9% (95% CI 41.2-64.6%) (P ¼ 0.015), and 66.6% (95% CI 58.1-75.3%) and 52.9% (95% CI 41.2-64.6%) (P ¼ 0.02), respectively ( Figure 1) . The other statistically significant prognostic factor for OS was HLA matching (Po0.0001). In univariate analysis conditioning regimen and HLA matching appeared as significant prognostic factor for better OS with Bu-Cy200 and good-risk HLA matching, respectively. In multivariate analysis, HLA matching appeared as significant prognostic factor (Tables 2 and 3 ).
Disease-free survival At the study end, 123 patients were leukemia-free by 82 months of median time (0.8-269 m). Five-and 10-year DFS for all patients were 55.3 and 54.6%, respectively. By the Kaplan-Meier analysis, 5-and 10-year DFS were better for patients given Bu-Cy200 than TBI-Cy conditioning regimen with 62.4% (95% CI 53.7-71.1%) and 43.4% (95% CI 32.1-54.7%) (P ¼ 0.005), respectively, and 62.4% (95% CI 53.7-71.1) and 41.9% (95% CI 30.6-53.2%) (P ¼ 0.005) at 5 and 10 years, respectively (Figure 2 ). In addition to conditioning regimen, HLA matching was the other significant impact factor for DFS. The results of univariate analysis are shown in Table 2 . In multivariate analysis, HLA matching still remained significant prognostic factor for better DFS at 5 years, whereas Bu-Cy200 and HLA matching appeared as significant prognostic factors for better DFS at 10 years (Table 3) .
Relapse
Any type of relapse after HSCT was registered, that is, 45% of leukemic cells in marrow aspiration, detection of leukemic cells outside BM (skin, central nervous system and so on) or positive molecular disease-above significant level-on at least two consecutive molecular controls. During the study, 64 patients relapsed with median time of 7.5 months (0.4-171). Five-year CI of relapse were 30.4% for all patients, 28 (95% CI 21.1-37.3%) and 32% (95% CI 24.2-40.4%) for patients who received Bu-Cy200 and TBI-Cy, respectively (P ¼ 0.7) (Figure 3) . By the Fine and Gray method, in multivariate analysis, none of the analyzed factors appeared as significant prognostic factors for relapse. 
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Treatment-related mortality At the end of the study, 39 patients died from a TRM with a median time of 8.2 months (95% CI 0.2-53.5). Five-year CI of TRM for all patients was 18%. Results were better for patients given Bu-Cy200 rather than for patients given TBI-Cy at 5 and 10 years (Bu-Cy200 20 and 20% vs TBI 16 and 28%, respectively) TRM was analyzed. By using Fine and Gray method, in univariate analysis, conditioning regimen and HLA matching appeared as statistically significant prognostic factor for TRM (Table 2) . In multivariate analysis, at 5 and 10 years, TBI-Cy and HLA matching still remained statistically significant factor that negatively influenced TRM (Table 3) .
Acute GvHD Eighty patients experienced aGvHDX2 by the median of day 24 post-HSCT (median time, range 7-810). In univariate analysis both conditioning regimen and HLA matching appeared as prognostic Bu-Cy conditioning regimen and sibling donor were considered as reference values (HR ¼ 1) for conditioning regimen and HLA matching, respectively.
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In multivariate analysis, TBI-Cy conditioning regimen appeared as the only worsening impact factor for aGvHD (Tables 2 and 3 ).
Chronic GvHD
Thirty-three patients presented with either limited or extensive chronic GvHD. Five-and 10-year cumulative incidence of cGvHD was 16.7% (95% CI: 11.6-22.6). In univariate analysis, both conditioning regimen and HLA matching appeared as prognostic factors for both limited and extensive cGvHD incidence. In multivariate analysis, TBI-Cy conditioning regimen appeared as the only worsening impact factor for cGvHD at 5 years (Tables 2  and 3) . Table 1 and Table 3 present the relative risk for 5-and 10-year OS, DFS, TRM, aGvHD end cGvHD in univariate and multivariate analysis, respectively. In univariate analysis, conditioning regimen (Bu-Cy200 vs TBI-Cy) and HLA matching appeared as the only statistically significant prognostic factors. The age at transplant has had no impact.
In multivariate analysis, HLA matching appeared as the only significant prognostic factor for OS. Conditioning regimen and HLA matching appeared as significant prognostic factors for DFS, TRM, and both acute and chronic GvHD.
DISCUSSION
The role of HSCT for pediatric patients with AML still remains discussed and controversial. [19] [20] [21] Indications for HSCT, donor type and stem cell sources varied over the time. However, in 2013, most cooperative groups indicate allogeneic SCT for patients with highrisk factors from either sibling or alternative donor. Both chemobased and TBI-based conditioning regimens still remain administered. 12, 21 In 1994, Michel et al., published a previous French study comparing two different Bu-based conditioning regimen. 5 In this study, the authors reported better results for patients who received 200 mg/kg as total dose of CY rather than those who received 120 mg/kg. Then, for the current retrospective report of pediatric population who received HSCT for AML in CR1, we excluded patients who received BU-CY 120. Irrespective of the considered end point, Bu-Cy200 association allowed statistically significant better outcome than TBI-Cy association. In the multivariate analysis, two factors appeared as statistically significant to enhance results: Bu-Cy200 conditioning regimen and HLA matched donor. In the Sisler et al. retrospective international multi-center study published in 2009 that analyzed 241 pediatric patients transplanted for AML in CR2 or more, the authors reported no differences for both OS and of relapseincidence between Bu-based and TBI-based conditioning regimen in pediatric patients transplanted for AML beyond CR1. 22 In multivariate analysis, conditioning regimen did not independently influence rates of OS, EFS, relapse or TRM. Nevertheless, the authors claimed their preference for Bu-Cy-based conditioning regimen because of possible expected lower rate of severe and late complications after BU than after TBI as described in different papers. 23, 24 By contrast, in a meta-analysis published in 2010, ShiXia et al., have selected 13 different publications regarding both lymphoblastic and myeloid acute leukemia mainly in adult patients. 25 After stratification by acute leukemia type, they concluded in favor of TBI-based one with lower rate of relapse and best TRM. But, as with Sisler et al., 22 they have some concern regarding TBI in children and the same interrogations regarding the possible benefit of IV-BU. In another slightly older metaanalysis comparing the use of Bu-Cy vs TBI-Cy regimen in patients with either acute or chronic leukemia, TBI regimen seemed to be superior to Bu-Cy regimen with significant results for OS, TRM and relapse. 26 However, only one out of five prospective studies used in this meta-analysis was about AML patients only. Finally, in 2010, Niewerth et al. 21 published a review on allogeneic HSCT for newly diagnosed pediatric AML where both chemo-based and TBI-based conditioning regimens were mentioned.
The patient cohort we report was treated before 2005, that is, before the development of so-called reduced intensity conditioning regimen for pediatric population. Initially, conditioning regimens were designed to be both myeloablative and immunosuppressive. Myeloablation has two different goals: anti-leukemic effect by decreasing the tumor burden and 'mechanical' effect by emptying BM niche. Immunosuppressive effect was required to ensure engraftment. 4, 27, 28 Historically, combination of CY (Cy 120 mg/kg) and TBI was the most used conditioning regimen. 25, 28, 29 Radiation-free regimen had been proven effective for eradication of leukemia and sufficiently immunosuppressive for engraftment in HLA-matched sibling transplantation. Because of higher incidence of treatmentrelated mortality with CY at the dose of 200 mg/kg in adult patients, it was reduced to 120 mg/kg in the 80 s. 30 However, Michel et al. 5 demonstrated both the feasibility and the better efficacy of Bu-Cy200 in pediatric population. The late effects of either TBI or Bu were different: TBI appeared to be associated with more late complications such as growth abnormalities, osteoarticular complications, cataract, secondary malignancies and cognitive issues than BU. 26, 31, 32 On the other hand, Bu seemed to be responsible of more early toxicity with more venoocclusive disease, hemorrhagic cystitis and interstitial pneumonia than TBI and to be responsible of more irreversible alopecia. 22, 25, 33 We may postulate that the availability of IV-Bu associated to dose adjustment either to body weight or to individual pharmacokinetics study improve the results for both relapse incidence and-may be-early and late toxicities. Even though fractioned TBI seems to give superior results regarding relapse and OS rates while limiting adverse effects on the other tissues comparing to single-dose TBI, the huge concerns regarding secondary malignancies and growth, hormonal and metabolic disorders still remain crucial, particularly in pediatric population with expected long-time survival. 26, 28, 34 Some alternative regimens have been used and reported but failed to strongly demonstrate advantage because of a too small cohort or a higher number of early relapse and regimen-related deaths. 29, 32, [35] [36] [37] Much progress was done in the HSCT field from 1990s: improvement in HLA typing, improvement of supportive care, more available immunosuppressive drugs, improvement in laboratory cellular therapy settings, better understanding and monitoring of minimal residual disease. However, we have to continue our efforts and research in order to improve global results, that is, disease control and both acute and late side effect. Gyurkocza et al. 38 recently reported a multi-center, retrospective study of 274 adult patients who underwent SCT after nonmyeloablative regimen (TBI 2 Gy with or without fludarabine). This regimen had relied almost entirely on GVL effect for treating AML. They were well tolerated and associated with improved OS rates. Authors reported rapid immune reconstitution and then, fewer deaths after infections. However, there was a higher relapse rate than previously reported in patients with either advanced disease or unfavorable cytogenetics. 38 In another study Mohty et al.
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reported that RIC-alloSCT, for patients with high-risk leukemic features, and/or high-risk clinical features, should be proposed as it represents a valid option. With this retrospective study, despite the bias linked to this study type, we confirm and recommend as it has already been implemented in therapeutic protocols to avoid TBI-based conditioning for pediatric patients who have AML with HSCT indication in CR1 according to current recommendations; having the notion that the new recommendations are more stringent than those which we used.
